Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

NCT03237325 is registered in ClinicalTrials.gov with Soligenix as lead sponsor.

NCT NCT03237325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03237325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Soligenix
Phase
Phase 3
Overall status
Completed
Start date
December 4, 2017
Completion date
June 24, 2021
Enrollment
266 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

oral mucositis, squamous cell carcinoma of the oral cavity and oropharynx